BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BioCentury | May 24, 2019
Company News

Novartis breast cancer drug marks first approval of PI3Kα inhibitor

Piqray alpelisib became the first FDA-approved PI3Kα inhibitor on Friday, as well as the first novel drug approved under the agency's Real-Time Oncology Review pilot program. FDA approved the breast cancer drug about three months...
BioCentury | May 24, 2019
Company News

AveXis says label makes Zolgensma gene therapy ‘treatment of choice’ for newly diagnosed SMA

Gene therapy Zolgensma from Novartis’ AveXis unit received a label from FDA that will allow it to become the “treatment of choice” for newly diagnosed spinal muscular atrophy patients, according to the company, as well...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Neurology

INDICATION: Fragile X syndrome Mouse studies suggest an FMR1 peptide could help treat fragile X syndrome. In a mouse model of fragile X syndrome, a 298-mer human FMR1 peptide containing the N-terminal domain normalized the...
BioCentury | Nov 16, 2018
Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
BioCentury | Nov 15, 2018
Financial News

Neurology company Cadent emerges with $40M series B

Cadent Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with news of a $40 million tranched series B round to bring its lead compound through Phase II trials to treat essential tremor and spinocerebellar ataxia (SCA)....
BioCentury | Oct 31, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Animal models E-cadherin (CDH1)-deficient mice with activated PI3KCA could be used to screen therapies for invasive lobular breast carcinoma. Mice engineered to express mutant, inactive CHD1 and constitutively active PI3KCA recapitulated multiple features of...
BioCentury | Aug 31, 2018
Company News

Urovant gets rights to gene therapy for overactive bladder

Ion Channel Innovations LLC (Ardsley, N.Y.) granted Urovant Sciences Ltd. (Basel, Switzerland) rights to develop and commercialize hMaxi-K, a gene therapy in development for overactive bladder. Next year, Urovant plans to start a Phase II...
BioCentury | Aug 31, 2018
Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...
BioCentury | Aug 28, 2018
Company News

Roivant units Urovant, Dermavant in deals as NEA’s Torti joins ‘vant’ team

Two Roivant Sciences GmbH (Basel, Switzerland) subsidiaries struck deals on Tuesday, with Urovant Sciences gaining rights to a gene therapy for overactive bladder and Dermavant Sciences receiving a $100 million investment tied to its tapinarof....
Items per page:
1 - 10 of 72